Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fuji Pharma CoFRA:FUP 89 EV-to-EBIT is 19.13 as of Jul. 31, 2026, which is 54% above its 10-year median of 12.42. GuruFocus rates FRA:FUP with a GF Score™ of 89/100 and a GF Value™ of €9.78. The stock has 3 warning signs investors should review. Among 692 Drug Manufacturers companies, Fuji Pharma Co ranks worse than 60.12% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Fuji Pharma Co's Enterprise Value for the quarter that ended in Mar. 2026 was €439.1 Mil.
Fuji Pharma Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fuji Pharma Co EV-to-EBIT Related Terms
Fuji Pharma Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Fuji Pharma Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fuji Pharma Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fuji Pharma Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fuji Pharma Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Fuji Pharma Co's EV-to-EBIT falls into.
Fuji Pharma Co's current Enterprise Value is €364.5 Mil.
Fuji Pharma Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fuji Pharma Co (FRA:FUP) has a EV-to-EBIT of 19.13 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fuji Pharma Co and its competitors. This is 54% above median its historical median of 12.42. Over the past decade, Fuji Pharma Co's EV-to-EBIT has ranged from 6.44 to 28.05. According to the industry distribution chart, Fuji Pharma Co ranks #416 out of 692 companies in the Drug Manufacturers industry, placing it in the top 60.1%.
Is Fuji Pharma Co's EV-to-EBIT too high?
Fuji Pharma Co's current EV-to-EBIT of 19.13 is 54% above median its 10-year median of 12.42. Over the past 10 years, this metric has ranged from a low of 6.44 to a high of 28.05. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Fuji Pharma Co's value of 19.13 is 21.3% above this industry median. Based on the distribution chart, Fuji Pharma Co ranks #416 out of 692 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Fuji Pharma Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Fuji Pharma Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fuji Pharma Co ranks #416 out of 692 companies for EV-to-EBIT. This places Fuji Pharma Co in the lower half of its industry. The industry median EV-to-EBIT is 15.77. Fuji Pharma Co's value of 19.13 is 21.3% above this benchmark. Historically, Fuji Pharma Co's own EV-to-EBIT has ranged from 6.44 to 28.05 over the past decade. While the company's 10-year median is 12.42 vs. the industry median of 15.77, Fuji Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fuji Pharma Co's current EV-to-EBIT of 19.13 is 21.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fuji Pharma Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fuji Pharma Co's current EV-to-EBIT is 19.13, which is 54% above median its own 10-year median of 12.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuji Pharma Co stock overvalued right now?
Fuji Pharma Co (FRA:FUP) has a current EV-to-EBIT of 19.13. The stock's GF Value™ is €9.78, compared to a current price of €9.95 — trading 1.7% above its estimated fair value. The current EV-to-EBIT is 19.13, which is 54% above median its 10-year median of 12.42 and 21.3% above the Drug Manufacturers industry median of 15.77. Fuji Pharma Co's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Fuji Pharma Co (FRA:FUP), the current EV-to-EBIT is 19.13 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fuji Pharma Co (FRA:FUP) Overvalued in 2026?
Based on GuruFocus' analysis, Fuji Pharma Co stock appears to be overvalued.
The current stock price of €9.95 is trading 1.7% above its estimated GF Value™ of €9.78.
Key valuation signals for FRA:FUP:
EV-to-EBIT: 19.13 (54% above median its 10-year median of 12.42)
GF Value™: €9.78 vs. price of €9.95 (1.7% above fair value)
Industry Position: 21.3% above the Drug Manufacturers median (#416 of 692)
No single metric tells the full story. See the FRA:FUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fuji Pharma Co Ltd is involved in the development, manufacture, and marketing of pharmaceutical products, such as injection agents, internal drugs, drugs for external use, and diagnostic products. The group consists of a single segment, the pharmaceutical business.
89GF Score
Get the complete analysis for FRA:FUP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FUP has been successfully added to your 
